SCHEMBL7794556

SCHEMBL7794556

CCOC(=O)C1CCN(c2nc(Cc3ccc4c(c3)OCO4)c3c(N)c(Cl)ccc3n2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.46
PDE4A P27815 2/20 0.46
PDE4B Q07343 2/20 0.46
PDE4C Q08493 2/20 0.46
PDE4D Q08499 2/20 0.46
PDE5A O76074 2/20 0.45
PDE2A O00408 1/20 0.44
PDE1A P54750 1/20 0.44
PDE1B Q01064 1/20 0.44
PDE1C Q14123 1/20 0.44
POLB P06746 3/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 1/20 0.44
KDM4E B2RXH2 5/20 0.43
RXFP1 Q9HBX9 1/20 0.43
LGMN Q99538 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
MAPT P10636 1/20 0.41
SHMT2 P34897 1/20 0.41
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7794732 0.89 PDE4A (0.49) ALDH1A1PDE4APDE4BPDE4CPDE4D
SCHEMBL149749 0.89 PDE4A (0.57) ALDH1A1PDE4APDE4BPDE4CPDE4D
Hydrochloric Acid SCHEMBL28844121 0.88 PDE4A (0.57) ALDH1A1PDE4APDE4BPDE4CPDE4D
SCHEMBL2232147 0.87 PDE5A (0.58) ALDH1A1PDE4APDE4BPDE4CPDE4D
SCHEMBL7796197 0.85 PDE4A (0.44) PDE4APDE4BPDE4CPDE4DPDE5A
SCHEMBL29801535 0.82 LTB4R (0.43) PDE4APDE4BPDE4CPDE4DPDE5A
SCHEMBL27379808 0.81 LTB4R (0.43) ALDH1A1PDE4APDE4BPDE4CPDE4D
SCHEMBL27355398 0.81 ALDH1A1 (0.43) ALDH1A1PDE5APOLBNPC1RAB9A
SCHEMBL8863081 0.80 PDE4A (0.51) ALDH1A1PDE4APDE4BPDE4CPDE4D
SCHEMBL7796503 0.78 PDE4A (0.53) ALDH1A1PDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010031760-A1 Method of treating a patient having precancerous lesions with quinazoline derivatives PAMUKCU RIFAT (US) 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031760-A1 Method of treating a patient having precancerous lesions with quinazoline derivatives MKI67, PCNA, NQO2 ALDH1A1 565/4885PDE4A 1596/4885PDE4B 1852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.